TABLE 2.

Univariate and multivariable analysis of clinical and molecular risk factors for myelofibrosis‐free survival (MFS) among 718 patients with essential thrombocythemia from University of Florence cohort, Italy

Clinical and laboratory variables	Univariate analysis p a (HR; 95% CI)	Multivariable analysis b p a (HR; 95% CI)	Multivariable analysis c p a (HR; 95% CI)	Multivariable analysis d p a (HR; 95% CI)
White blood cells (×109/L) (continuous variable)	0.05 (0.9; 0.8–1)
White blood cells ≥11 × 109/L	0.07 (0.4; 0.1–1.1)
Hb (g/dl) (continuous variable)	0.4 (0.9; 0.7–1.1)
Hct levels (%) (continuous variable)	0.5 (0.9; 0.8–1.1)
Platelet count (×109/L) (continuous variable)	0.05 (0.9; 0.9–1)
Platelet count ≥1000 × 109/L	0.05 (0.5; 0.2–1)
Age >60 years	0.02 (1.9; 1.1–3.9)	0.005 (2.5; 1.3–4.9)	0.02 (3.8; 1.3–11.4)	0.05 (1.9; 0.9–3.5)
Age (continuous variable)	0.03 (1; 1–1.1)
Male sex	0.001 (2.4; 1.4–4.2)	0.02 (2.1; 1.2–3.9)	0.3 (1.7; 0.7–4.2)	0.01 (2; 1.2–3.5)
Constitutional symptoms	0.01 (2.6; 1.2–5.3)	0.06 2.1 (0.9; 4.7)	0.3 (2.6; 0.5–12.1)	0.04 (2.2; 1–4.8)
Palpable splenomegaly	0.002 (2.5; 1.4–4.5)	0.01 (2.1; 1.2–3.9)	0.003 (4.3; 1.7–11)	0.02 (2.1; 1.1–3.8)
Microcirculatory symptoms	0.5 (1.2; 0.7–2.2)
JAK2 mut	0.01 (0.5; 0.3–0.9)
CALR 1/1‐like and 2/2‐like	0.01 (2.1; 1.2–3.6)
MPL mut	0.008 3.2 (1.4–7.7)
TN	0.09 0.2 (0.02–1.3)
CALR 1/1‐like vs. 2/2‐like	0.04 (3.2; 1.1–9.3)
CALR 1/1‐like/MPL	<0.001 (3.8; 2.2–6.6)	<0.001 (3.4; 1.9–6.1)
JAK2V617F VAF >35% vs. ≤35%	<0.001 (5.9; 2.4–14.4)		0.003 (4.2; 1.6–10.8)
JAK2V617F > 35% vs. all the others	0.009 (2.2; 1.2–4)
CALR type 1/1‐like + MPL + JAK2V617F > 35% vs. all the others	<0.001 (6.1; 3.2–11.7)			<0.0001 (5.2; 2.7–10)

^a Significant p values are highlighted in bold.

^b Considering all ET cohort (n = 718) with CALR type 1/1‐like/MPL as molecular risk variable.

^c Considering only JAK2 patients (n = 471) with VAF >35% as molecular risk variable.

^d Considering all ET cohort (n = 718) with CALR type 1/1‐like/MPL/ JAK2 VAF >35% as molecular risk variable.